Collaboration to advance multiplexed biomarker panel for early Type 1 diabetes diagnosis

Genalyte (San Diego, CA) has launched a Type 1 diabetes multiplexed antigen panel that runs on the company's silicon photonics-driven Maverick detection system, and is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in Type 1 diabetes. The company is also collaborating with the Barbara Davis Center for Childhood Diabetes (BDC) at the University of Colorado School of Medicine (Aurora, CO) to further develop and test multiplexed antigen panels for the early detection of Type 1 diabetes.

Related: Multiplexed detection system from Genalyte garners CE mark approval
 
The T1D antigen panel was developed as part of the first phase of a Small Business Innovation Research (SBIR) grant awarded to the company to develop multiplexed assays for the early detection and monitoring of Type 1 diabetes.  The $500,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases also provides support for expansion of the approach to allow autoantibody response profiling by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.
 
George Eisenbarth, MD, PhD, and Liping Yu, MD, at BDC established assays for measuring islet autoantibodies, explains Martin Gleeson, PhD, chief scientific officer at Genalyte. Islet autoantobodies eventually destroy the pancreatic islet cells that produce insulin; to that end, the Maverick detection platform can detect and track the process from an early stage, when interventions to interrupt the disease process may be feasible, he says.
 
Available to diabetes researchers worldwide, the T1D antigen panel requires only a 2 to 5 μL serum or plasma sample and provides results in less than 15 minutes without the use of dyes, fluorescent probes, or radioactive labels. The panel measures autoantibodies to insulin, proinsulin, GAD 65, GAD 67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß), and ZnT8 (SLC30A8).

For more information, visit http://genalyte.com/maverick-type-1-diabetes-t1d-assay-kit/.         

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

POST A COMMENT

Related Articles

Silicone microspheres show promise for medical imaging, targeted drug delivery

Chemists have produced silicone microspheres that could enable next-generation medical imaging and targeted medicine.

Low-light CMOS biosensor enables detection of four copies of pathogen DNA per sample

Anitoa Systems has demonstrated handheld, real-time qPCR using its ultra-low-light CMOS biosensor.

Silver nanoclusters inside synthetic DNA have utility in bioimaging

A team of researchers has created nanoscale silver clusters with unique fluorescence properties important for bioimaging.

GWU installs correlative microscopy system at its new research facility

George Washington University will install a correlative light and electron microscopy system at its Science and Engineering Hall.

BLOGS

Single-molecule tracking promises discoveries, cures

New ways of imaging individual proteins and lipids will ultimately change science and medicine.

Growth in lasers for medicine

At the Lasers and Photonics Marketplace Seminar during SPIE Photonics West 2015, analyst Allen No...

Also at BiOS 2015

Although the BiOS Expo closes on Sunday, February 8, 2015, the conferences of the Biomedical Opti...

Most Popular Articles


CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2015. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS